Isomorphic Labs Secures $5 Billion Series C to Expand AI Drug Discovery

AI Insider

Source published: Site published:

Original article

Isomorphic
Isomorphic Labs announced a $5 billion Series C funding round to expand its AI-powered drug design platform.

Insider Brief

  • Isomorphic Labs announced a $5 billion Series C funding round to grow its AI drug design platform and move potential medicines closer to clinical trials.
  • Greenoaks and Sequoia Capital led the funding round. Andreessen Horowitz, Alphabet and several other new and existing investors also took part.
  • The company reported positive results from early testing of treatments for cancer and immune system diseases, as well as work with partners. The new funding will support further AI development and the expansion of its research and clinical development facilities.

PRESS RELEASE — Isomorphic Labs, an AI company that designs and develops new medicines, announced a $5 billion Series C funding round. Greenoaks and Sequoia Capital led the round, along with Andreessen Horowitz (a16z) and several other new investors. Alphabet also continued to make a major investment in the company. All existing investors also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic is expanding its own drug design system, called IsoDDE, and its pipeline of potential medicines designed with AI. The goal is to create the next generation of medicines. IsoDDE brings together several advanced AI models that can simulate how molecules behave. These models work across different areas of medicine and different types of drugs. IsoDDE searches through huge numbers of possible chemical structures. This helps Isomorphic's expert team design and improve molecules so they have the right features to work as medicines.

The simulation models in IsoDDE are designed to make predictions that are closer to what happens in real experiments. They give the company several ways to help develop new medicines. Isomorphic also uses powerful AI agents that can explore and reason about complex biological systems. Together, these tools are helping the company improve its pipeline of potential treatments in several areas. They are aimed at some of the hardest problems in drug discovery. This work has produced positive results in early testing, both in the company's own cancer and immune system disease programs and in projects with partners. These results are helping prepare the treatments for clinical trials.

The new funding will speed up Isomorphic's scientific work and the development of its own AI technology. The company plans to improve IsoDDE further and develop more advanced models that can study new areas of biology. It also plans to build a network of partners to improve understanding of the biological processes behind diseases. At the same time, the company is developing the global infrastructure needed to support future AI-powered bioengineering. Some of the money will also help build larger, scalable systems for research and clinical development that use AI from the start. These systems will support the company's efforts to move its potential medicines into clinical trials.

“When we founded Isomorphic, we believed that AI could help us understand and model biology at the most basic molecular level and greatly speed up this work,” said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs. “Our drug design engine is creating molecules with a level of precision and speed we have not seen before. This funding round will help us move faster. We will build advanced models of basic biological processes, improve our understanding of how diseases affect the whole body, and move our first treatment programs closer to clinical trials. Our goal is to make a real difference for patients.”

“Every week, our models help us make scientific advances that we can repeat,” said Max Jaderberg, President of Isomorphic Labs. “These advances directly improve the properties of molecules that could become new medicines. They also help us tackle some of the hardest problems in drug discovery. Our teams bring together leading machine learning researchers and highly skilled drug discovery experts. Together, they regularly solve complex biological problems that have held back traditional research for decades. We are turning our discoveries into potential medicines that could change lives. This work is supported by the infrastructure we are building for the future of bioengineering, with the backing of our investors.”

“Finding and developing new medicines is an optimization problem on an almost endless scale,” said Neil Mehta, Founder and Managing Partner of Greenoaks. “Isomorphic is changing this process. It is building deep learning systems that can predict complex biological behavior with remarkable accuracy and systematically show the way toward new medicines. We believe Demis, Max and the Isomorphic team are building the future of AI-powered drug discovery. We are proud to work with them on this important mission.”

“Isomorphic Labs is building the basic technology that will help shape the future of medicine,” said Konstantine Buhler, Partner at Sequoia Capital. “It is exciting to see the Isomorphic team turn advanced AI into a growing collection of potential medicines. Using AI to improve human health is one of the most important challenges of our generation. We are proud to lead this funding round together with Greenoaks and support further scientific discoveries in medicine.”